Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Brief Funct Genomics. 2020 May 20;19(3):175-182. doi: 10.1093/bfgp/elz042.


Chimeric antigen receptor(CAR) T-cell therapy has shown remarkable effects and promising prospects in patients with refractory or relapsed malignancies, pending further progress in the next-generation CAR T cells with more optimized structure, enhanced efficacy and reduced toxicities. The clustered regulatory interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) technology holds immense promise for advancing the field owing to its flexibility, simplicity, high efficiency and multiplexing in precise genome editing. Herein, we review the applications and explorations of CRISPR/Cas9 technology in constructing allogenic universal CAR T cells, disrupting inhibitory signaling to enhance potency and exploration of safer and more controllable novel CAR T cells.

Keywords: CAR T cells; CRISPR; Cas9; cancer immunotherapy; genome editing.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • CRISPR-Cas Systems / genetics*
  • Gene Editing / methods*
  • Humans
  • Immunotherapy, Adoptive / methods*